直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Petitioner Estopped Because References Reasonably Could Have Been Raised in Its Earlier IPR

September 06, 2016

Authored and Edited by Hala S. Mourad; Cory C. Bell

In Praxair Distribution, Inc. v. INO Therapeutics, LLC., IPR2016-00781, Paper 10 (Aug. 25, 2016), the Board denied Praxair’s inter partes review petition based on both estoppel under 35 U.S.C. § 315(e)(1) and the PTAB’s discretion under § 325(d).

The petition challenged the same claims of U.S. Patent No. 8,846,112 as a prior petition filed by Praxair, but based on two new textbook references. Praxair asserted that it did not cite the new references in the earlier IPR because it did not discover them before filing. As evidence, Praxair provided a list of exemplary search results from Cardinal Intellectual Property, Inc.

The Board based its estoppel determination on whether the new references were “prior art which a skilled searcher conducting a diligent search reasonably could have been expected to discover.” The Board found the single search report insufficient to show that a reasonable search was conducted, highlighting the following facts:

  • The report was by an “unidentified searcher of indeterminate skill and experience”
  • The report does not explain why the searcher “used certain keywords and keyword combinations”
  • The report was an “exemplary list”, and Praxair did not “explain whether [the new references] were encompassed by the initial search results but not selected for the exemplary list”
  • The “other articles by the author . . . were cited during prosecution” and obviousness testimony of Praxair’s expert suggested that a person of ordinary skill in the art would have sought out the new references.

The Board also exercised its discretion to deny Praxair’s petition under § 325(d). They reached this conclusion not only because “the same or substantially the same arguments” were previously presented but also because Praxair “should have been aware of the newly-cited . . . references when it filed the earlier Petition.”

Tags

America Invents Act (AIA), estoppel, Patent Trial and Appeal Board (PTAB), rules and rules of practice

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Cory C. Bell
Partner
Boston, MA
+1 617 646 1641
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Hybrid Conference

Intellectual Property Law Institute 2026 – New York

September 28-29, 2026

New York

Lecture

Resolving Patent Suits Without Settlement Payments

September 3, 2026

Virtual

Conference

Finnegan IP Summit 2026: Celebrating an Inclusive Talent Pipeline

August 11-13, 2026

Washington, DC

Conference

13th Annual Summit for Women Leaders in Life Sciences Law

July 29-30, 2026

Boston

Webinar

Successful Strategies to Win Alice Motions and Fee Awards in Patent Cases Against Non-Practicing Entities

July 22, 2026

Webinar

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Articles

This Article Was Written Entirely by AI — Welcome to Synthetic Patent Litigation

July/August 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP